Objective The role of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of
type 2 diabetes is debated; many recent trials, which were not included in previous meta …

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are a valuable addition to
the type 2 diabetes armamentarium. They increase insulin secretion and reduce glucagon …

Established therapies for type‐2 diabetes effectively reduce blood glucose, but are often
associated with adverse effects that pose risks to patient's health or diminish adherence to …

Abstract Objective: Glucagon-like peptide-1 (GLP-1) receptor agonists are available for the
treatment of type 2 diabetes. We assessed the efficacy of exenatide and liraglutide to reach …

Failure of secretion of the incretin hormone glucagon-like peptide-1 (GLP-1) plays a
prominent role in type 2 diabetes, and restoration of GLP-1 action is an important therapeutic …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin
hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 …